| Diabetes Mellitus
Admelog vs Novolog
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Admelog vs Insulin Diluting Medium For Novolog with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInsulin Diluting Medium For Novolog has a higher rate of injection site reactions vs Admelog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Insulin Diluting Medium For Novolog but not Admelog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Admelog
Insulin Diluting Medium For Novolog
At A Glance
Subcutaneous, Continuous subcutaneous infusion (pump), Intravenous
Within 15 minutes before or immediately after meals
Rapid-acting insulin analog
SC injection
Pre-meal
Rapid-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Individualize dose based on route of administration, metabolic needs, blood glucose monitoring, and glycemic control goal. Subcutaneous injection: Administer within 15 minutes before or immediately after a meal into abdominal wall, thigh, upper arm, or buttocks. Continuous subcutaneous infusion (insulin pump): Administer via pump in accordance with pump instructions; change reservoir at least every 7 days. Intravenous infusion: Administer only after dilution (0.1-1 unit/mL in 0.9% Sodium Chloride) under medical supervision. Rotate injection/infusion sites to reduce lipodystrophy risk.
Diabetes Mellitus Inject SC within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm; generally used with an intermediate- or long-acting insulin; may also be administered via continuous SC infusion pump or diluted to 0.05-1 unit/mL for IV infusion; individualize dose based on metabolic needs and blood glucose monitoring results.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro or any excipient in ADMELOG
- Episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or one of its excipients
Adverse Reactions
Most common (>=5%) Nasopharyngitis (13%), upper respiratory tract infection (6%).
Severe hypoglycemia 13.5% in type 1 diabetes (52 weeks), 2.4% in type 2 diabetes (26 weeks).
Postmarketing Medication errors with accidental insulin substitution, localized cutaneous amyloidosis at injection site.
Most common (>=5%) Headache, accidental injury, nausea, diarrhea (type 1 diabetes); hyporeflexia, onychomycosis, sensory disturbance, urinary tract infection, chest pain, skin disorder, abdominal pain, sinusitis (type 2 diabetes)
Serious Severe hypoglycemia, generalized allergy/anaphylaxis, hypokalemia, lipodystrophy, peripheral edema
Postmarketing Localized cutaneous amyloidosis at injection site, medication errors with insulin substitution, hyperglycemia or hypoglycemia associated with amyloidosis-related injection site changes
Pharmacology
Insulin lispro is a rapid-acting insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Rapid-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with peak glucose-lowering effect 1-3 hours after SC injection and duration of action 3-5 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Admelog
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Insulin Diluting Medium For Novolog
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Admelog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Insulin Diluting Medium For Novolog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Admelog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Insulin Diluting Medium For Novolog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Admelog.
No savings programs available for Insulin Diluting Medium For Novolog.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdmelogView full Admelog profile
Insulin Diluting Medium For NovologView full Insulin Diluting Medium For Novolog profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.